Imugene (ASX:IMU) secures core US patent

Imugene (ASX:IMU) secures core US patent


Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth factor immunotherapy platform.

The patent protects the method of composition and method of use of Imugene’s Ohio State University licensed vaccines out to 2035.

The company says this is a core US patent in the world’s largest pharmaceutical market.

Shares in Imugene (ASX:IMU) are trading 5.9 per cent higher at 5 cents.
Copyright 2020 – Finance News Network

Source: Finance News Network

Share this post